Progress in medicinal chemistry最新文献_第5页

Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease. LRRK2抑制剂治疗帕金森病的研究进展

Progress in medicinal chemistry Pub Date : 2017-01-01 Epub Date: 2017-01-04 DOI: 10.1016/bs.pmch.2016.11.002

K V Christensen, G P Smith, D S Williamson

引用次数: 18

Recent Progress in the Discovery and Development of TRPA1 Modulators. TRPA1调制剂的研究进展。

Progress in medicinal chemistry Pub Date : 2017-01-01 Epub Date: 2017-02-06 DOI: 10.1016/bs.pmch.2016.11.003

S Skerratt

{"title":"Recent Progress in the Discovery and Development of TRPA1 Modulators.","authors":"S Skerratt","doi":"10.1016/bs.pmch.2016.11.003","DOIUrl":"https://doi.org/10.1016/bs.pmch.2016.11.003","url":null,"abstract":"TRPA1 is a well-validated therapeutic target in areas of high unmet medical need that include pain and respiratory disorders. The human genetic rationale for TRPA1 as a pain target is provided by a study describing a rare gain-of-function mutation in TRPA1, causing familial episodic pain syndrome. There is a growing interest in the TRPA1 field, with many pharmaceutical companies reporting the discovery of TRPA1 chemical matter; however, GRC 17536 remains to date the only TRPA1 antagonist to have completed Phase IIa studies. A key issue in the progression of TRPA1 programmes is the identification of high-quality orally bioavailable molecules. Most published TRPA1 ligands are commonly not suitable for clinical progression due to low lipophilic efficiency and/or poor absorption, distribution, metabolism, excretion and pharmaceutical properties. The recent TRPA1 cryogenic electron microscopy structure from the Cheng and Julius labs determined the structure of full-length human TRPA1 at up to 4Å resolution in the presence of TRPA1 ligands. This ground-breaking science paves the way to enable structure-based drug design within the TRPA1 field.","PeriodicalId":20755,"journal":{"name":"Progress in medicinal chemistry","volume":"56 ","pages":"81-115"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.pmch.2016.11.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34831309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 26

Preface. 前言。

Progress in medicinal chemistry Pub Date : 2017-01-01 DOI: 10.1016/S0079-6468(17)30016-4

D R Witty, B Cox

引用次数: 0

Index 指数

Progress in medicinal chemistry Pub Date : 2016-02-04 DOI: 10.1016/s0079-6468(16)00010-2

引用次数: 0

Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors. 发现去泛素化酶抑制剂的最新进展。

Progress in medicinal chemistry Pub Date : 2016-01-01 Epub Date: 2016-01-12 DOI: 10.1016/bs.pmch.2015.10.002

Mark Kemp

引用次数: 0

Preface. 前言。

Progress in medicinal chemistry Pub Date : 2015-01-01 DOI: 10.1016/S0079-6468(15)00009-0

Geoff Lawton, David Witty

引用次数: 0

A new era for chagas disease drug discovery? 恰加斯病药物发现的新时代?

Progress in medicinal chemistry Pub Date : 2015-01-01 Epub Date: 2015-01-17 DOI: 10.1016/bs.pmch.2014.12.001

Martine Keenan, Jason H Chaplin

引用次数: 37

Recent advances in cancer therapeutics. 癌症治疗的最新进展。

Progress in medicinal chemistry Pub Date : 2015-01-01 Epub Date: 2015-01-23 DOI: 10.1016/bs.pmch.2014.11.002

Nicola Chessum, Keith Jones, Elisa Pasqua, Michael Tucker

{"title":"Recent advances in cancer therapeutics.","authors":"Nicola Chessum, Keith Jones, Elisa Pasqua, Michael Tucker","doi":"10.1016/bs.pmch.2014.11.002","DOIUrl":"https://doi.org/10.1016/bs.pmch.2014.11.002","url":null,"abstract":"In the past 20 years, cancer therapeutics has undergone a paradigm shift away from the traditional cytotoxic drugs towards the targeting of proteins intimately involved in driving the cancer phenotype. The poster child for this alternative approach to the treatment of cancer is imatinib, a small-molecule kinase inhibitor designed to target chronic myeloid leukaemia driven by the BCR-ABL translocation in a defined patient population. The improvement in survival achieved by treatment of this patient cohort with imatinib is impressive. Thus, the aim is to provide efficacy but with low toxicity. The role of the medicinal chemist in oncology drug discovery is now closely aligned with the role in most other therapeutic areas with high-throughput and/or fragment-based screening, structure-based design, selectivity, pharmacokinetic optimisation and pharmacodynamic biomarker modulation, all playing a familiar part in the process. In this chapter, we selected four areas in which compounds are either approved drugs or in clinical trials. These are chaperone inhibitors, kinase inhibitors, histone deacetylase inhibitors and inhibitors of protein-protein interactions. Even within these areas, we have been selective, particularly for kinase inhibitors, and our aim has been to exemplify newer approaches and novel aspects of medicinal chemistry. ","PeriodicalId":20755,"journal":{"name":"Progress in medicinal chemistry","volume":"54 ","pages":"1-63"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.pmch.2014.11.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33092481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 32

Imaging in drug development. 药物开发中的成像。

Progress in medicinal chemistry Pub Date : 2015-01-01 Epub Date: 2014-11-27 DOI: 10.1016/bs.pmch.2014.10.002

James Nairne, Peter B Iveson, Andreas Meijer

引用次数: 11

Fluorine in medicinal chemistry. 药物化学中的氟。

Progress in medicinal chemistry Pub Date : 2015-01-01 Epub Date: 2015-01-07 DOI: 10.1016/bs.pmch.2014.11.001

Steven Swallow

引用次数: 564